A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Phase 1RecruitingNCT06982131

Hoffmann-La Roche40 enrolled

Overview

This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered RO7795081 and the effect of a steady-state dose of orally administered RO7795081 on the pharmacokinetics of pitavastatin and rosuvastatin in otherwise healthy, overweight or obese adult participants.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Overweight Obesity

Interventions

RO7795081

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy participants with no clinically relevant findings on physical examination at screening and at baseline (including detailed medical and surgical history, vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis); with no suspicion of cognitive impairment or dementia as judged by the Investigator; who are not under judicial supervision, guardianship, or curatorship. * Body Mass Index (BMI) ≥27.0 kg/m\^2 at screening and on Day -1 of Period 1 * Stable body weight (defined as \<5% gain or loss) in the 2 months prior to screening as per verbal report by the participant and for the period between screening and Day -1 of Period 1 as per measured weight * Agreement to adhere to the contraception requirements Exclusion Criteria: * Pregnant, breastfeeding, or intending to become pregnant during the study * Any condition or disease detected during the medical interview or physical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator * History or presence of any clinically significant cardiovascular, broncho-pulmonary, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, psychiatric, or metabolic disorders, allergic diseases, hypofertility, cancer, or cirrhosis * History or evidence of any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs * History of convulsions (other than benign febrile convulsions of childhood) including epilepsy, or personal history of significant cerebral trauma or CNS infections (e.g., meningitis) * History of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma

Outcomes

Primary Outcomes

Incidence and Severity of Adverse Events

Time frame: From the first dose of study treatment until the final visit (up to 111 days)

Incidence of Abnormal Clinical Laboratory Test Results

Time frame: From the first dose of study treatment until the final visit (up to 111 days)

Incidence of Abnormal Vital Sign Assessments

Time frame: From the first dose of study treatment until the final visit (up to 111 days)

Incidence of Abnormal Electrocardiogram Parameters

Time frame: From the first dose of study treatment until the final visit (up to 111 days)

Maximum Plasma Concentration Observed (Cmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5

Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5

Area Under the Plasma Concentration-Time Curve (AUC) from Time 0 to the Last Measurable Concentration (AUClast) of Rosuvastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5

AUC from Time 0 to Infinity (AUCinf) of Rosuvastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 1 and 4: predose and postdose at prespecified times on Days 1 to 5

Cmax of Pitavastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4

Tmax of Pitavastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4

AUClast of Pitavastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4

AUCinf of Pitavastatin, Administered Alone and in Combination with RO7795081

Time frame: Periods 2 and 5: predose and postdose at prespecified times on Days 1 to 4

Secondary Outcomes

Plasma Concentration of RO7795081 Over Time, Administered Alone and in Combination with Rosuvastatin and Pitavastatin

Time frame: Period 3: predose and postdose at prespecified times from Days 2 to 49; Period 4: predose and postdose at prespecified times on Days 1 to 4; Periods 4: predose and postdose at prespecified times on Days 1 to 9

Cmax of RO7795081, Administered Alone and in Combination with Rosuvastatin and Pitavastatin

Tmax of RO7795081, Administered Alone and in Combination with Rosuvastatin and Pitavastatin

AUClast of RO7795081, Administered Alone and in Combination with Rosuvastatin and Pitavastatin

AUCinf of RO7795081, Administered Alone and in Combination with Rosuvastatin and Pitavastatin

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts